Diabetes
| Incretin Based Therapies
Diabetes
Incretin Based Therapies
Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data
book_2
Source:
ADA 2020 - Poster session
calendar_today
Published on Medfyle:
July 2020
headphones
4
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- New real-world data showed dulaglutide had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment.
- At 6 months, people taking dulaglutide showed higher adherence and persistence than people taking semaglutide or exenatide.
- Further, significantly fewer people discontinued treatment with dulaglutide compared to semaglutide or exenatide.
- Adherence and persistence are integral factors when applying a holistic approach to patient care; the new real-world data shows that dulaglutide provides significantly better outcomes in this regard, when compared to weekly injections of semaglutide or exenatide in people with type 2 diabetes.
